Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Eimeren, T. (Thilo) van | - |
dc.creator | Antonini, A. (Angelo) | - |
dc.creator | Berg, D. (Daniela) | - |
dc.creator | Bohnen, N. (Nico) | - |
dc.creator | Ceravolo, R. (Roberto) | - |
dc.creator | Drzezga, A. (Alexander) | - |
dc.creator | Höglinger, G.U. (Günter U.) | - |
dc.creator | Higuchi, M. (Makoto) | - |
dc.creator | Lehericy, S. (Stephane) | - |
dc.creator | Lewis, S. (Simon) | - |
dc.creator | Monchi, O. (Oury) | - |
dc.creator | Nestor, P. (Peter) | - |
dc.creator | Ondrus, M. (Matej) | - |
dc.creator | Pavese, N. (Nicola) | - |
dc.creator | Peralta, M.C. (María Cecilia) | - |
dc.creator | Piccini, P. (Paola) | - |
dc.creator | Pineda-Pardo, J.A. (José Ángel) | - |
dc.creator | Rektorova, I. (Irena) | - |
dc.creator | Rodriguez-Oroz, M.C. (María Cruz) | - |
dc.creator | Rominger, A. (Axel) | - |
dc.creator | Seppi, K. (Klaus) | - |
dc.creator | Stoessl, A.J. (A. Jon) | - |
dc.creator | Tessitore, A. (Alessandro) | - |
dc.creator | Thobois, S. (Stephane) | - |
dc.creator | Kaasinen, V. (Valtteri) | - |
dc.creator | Wenning, G. (Gregor) | - |
dc.creator | Siebner, H.R. (Hartwig R.) | - |
dc.creator | Strafella, A.P. (Antonio P.) | - |
dc.creator | Rowe, J.B. (James B.) | - |
dc.date.accessioned | 2022-06-09T12:18:56Z | - |
dc.date.available | 2022-06-09T12:18:56Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Eimeren, T. (Thilo) van; Antonini, A. (Angelo); Berg, D. (Daniela); et al. "Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System". Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 11, 2019, 301 - 309 | es |
dc.identifier.issn | 2352-8729 | - |
dc.identifier.uri | https://hdl.handle.net/10171/63635 | - |
dc.description.abstract | Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders. Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies. Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression). Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials. | es_ES |
dc.description.sponsorship | This work was supported by the EU Joint Program of Neurodegenerative Diseases (JPND, http://www.neurodegenerati onresearch.eu). Thilo van Eimeren received honoraria from Lilly, Shire and is supported by grants from DFG, Leibniz Foundation, JPND. Angelo Antonini received consultancies from BIAL, Lundbeck, UCB Pharma, Zambon, AbbVie and honoraria for talks from AbbVie, BIAL, Lundbeck, UCB Pharma, Mundipharma, Zambon and is supported by grants from Horizon2020, JPND, Chiesi Pharmaceuticals, AbbVie. Daniela Berg received honoraria from Biogen, BIAL, Lundbeck, UCB Pharma GmbH, AbbVie, Zambon and is supported by grants from Michael J. Fox Foundation, Janssen Pharmaceutica N.V., German Parkinson’s Disease Association (dPV), BMWi, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, TEVA Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, Damp foundation. Nico Bohnen received grants from the NIH (RO1 NS070856 and P50 NS091856), US Department of Veterans Affairs (I01 RX000317), the Michael J. Fox Foundation, Axovant Sciences and Chase Pharmaceuticals. Roberto Ceravolo received fees for talks and consultancy from General Electric, Zambon, UCB Pharma. G€unter U H€oglinger received research support from Neuropore, GE Health; Research collaborations with Orion, Prothena; consultant for Abbvie, Alzprotect, Asceneuron, Biogen, BristolMyers Squibb, Novartis, Roche, UCB; honoraria for scientific presentations from Abbvie, Roche, Teva, UCB, Zambon. Stephane Lehericy received grants from “Investissements d’avenir” (grant number ANR-10- IAIHU-06 and ANR-11-INBS-0006). Research grant from Biogen Inc. Simon Lewis is supported by an NHMRC-ARC Dementia Fellowship #1110414. Matej Ondrus is an employee of AXON Neuroscience SE. Irena Rektorova has received honoraria as associate editor (Parkinsonism and related disorders) from Elsevier Publishers, Amsterdam, The Netherlands, and is supported by grants H2020-MSCA RISE, IMI H2020, and grants from the Agency of Health Research of the Ministry of Health, Czech Republic. Klaus Seppi received personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Gr€unenthal, and Abbvie, honoraria from the International Parkinson and Movement Disorders Society, research grants from FWF Austrian Science Fund, Michael J. Fox Foundation, and International Parkinson and Movement Disorder Society. Stephane Thobois reports grants from Fondation pour la Recherche Medicale, from France Parkinson, Fondation Neurodis, ANR, PHRC and personal fees from UCB, Medtronic, Teva, St Jude, Novartis, Aguettant, Zambon, Abbvie. Valtteri Kaasinen has received honoraria from Abbvie Finland, Orion Pharma, GE Healthcare, Teva, Abbvie, NordicInfu Care Ab; consultant for Zambon. Gregor Wenning has received honoraria from Abbvie Biogen Lundbeck Novartis Ono Prana Theravance. Hartwig R Siebner has received honoraria as speaker and consultant from Sanofi Genzyme, Denmark and as senior editor (NeuroImage) from Elsevier Publishers, Amsterdam, The Netherlands, and royalties as book editor from Springer Publishers, Stuttgart, he has received a research fund from Biogen-Idec. Antonio P. Strafella is supported by Canadian Institutes of Health Research (MOP-136778) and Canada Research Chair Program. James B Rowe has received honoraria/consultancy fees from Biogen and Asceneuron, and research grants from AZ-Medimmune, Lilly, Janssen and the Dementias Platform UK. His principal funding is from Wellcome Trust, Medical Research Council and the National Institute for Health Research. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Biomarker | es_ES |
dc.subject | Trials | es_ES |
dc.subject | PSP | es_ES |
dc.subject | MSA | es_ES |
dc.subject | CBD | es_ES |
dc.subject | CBS | es_ES |
dc.subject | Neurodegeneration | es_ES |
dc.subject | Biomarker | es_ES |
dc.subject | Multicentric | es_ES |
dc.subject | Multisite | es_ES |
dc.subject | Neuroimaging | es_ES |
dc.subject | Harmonization | es_ES |
dc.subject | PET | es_ES |
dc.subject | MRI | es_ES |
dc.title | Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | es_ES |
dc.identifier.doi | 10.1016/j.dadm.2019.01.011 | - |
dadun.citation.endingPage | 309 | es_ES |
dadun.citation.publicationName | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | es_ES |
dadun.citation.startingPage | 301 | es_ES |
dadun.citation.volume | 11 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.